Cargando…

An open label, non-randomized study assessing a prebiotic fiber intervention in a small cohort of Parkinson’s disease participants

A pro-inflammatory intestinal microbiome is characteristic of Parkinson’s disease (PD). Prebiotic fibers change the microbiome and this study sought to understand the utility of prebiotic fibers for use in PD patients. The first experiments demonstrate that fermentation of PD patient stool with preb...

Descripción completa

Detalles Bibliográficos
Autores principales: Hall, Deborah A., Voigt, Robin M., Cantu-Jungles, Thaisa M., Hamaker, Bruce, Engen, Phillip A., Shaikh, Maliha, Raeisi, Shohreh, Green, Stefan J., Naqib, Ankur, Forsyth, Christopher B., Chen, Tingting, Manfready, Richard, Ouyang, Bichun, Rasmussen, Heather E., Sedghi, Shahriar, Goetz, Christopher G., Keshavarzian, Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9938693/
https://www.ncbi.nlm.nih.gov/pubmed/36801916
http://dx.doi.org/10.1038/s41467-023-36497-x
_version_ 1784890687533088768
author Hall, Deborah A.
Voigt, Robin M.
Cantu-Jungles, Thaisa M.
Hamaker, Bruce
Engen, Phillip A.
Shaikh, Maliha
Raeisi, Shohreh
Green, Stefan J.
Naqib, Ankur
Forsyth, Christopher B.
Chen, Tingting
Manfready, Richard
Ouyang, Bichun
Rasmussen, Heather E.
Sedghi, Shahriar
Goetz, Christopher G.
Keshavarzian, Ali
author_facet Hall, Deborah A.
Voigt, Robin M.
Cantu-Jungles, Thaisa M.
Hamaker, Bruce
Engen, Phillip A.
Shaikh, Maliha
Raeisi, Shohreh
Green, Stefan J.
Naqib, Ankur
Forsyth, Christopher B.
Chen, Tingting
Manfready, Richard
Ouyang, Bichun
Rasmussen, Heather E.
Sedghi, Shahriar
Goetz, Christopher G.
Keshavarzian, Ali
author_sort Hall, Deborah A.
collection PubMed
description A pro-inflammatory intestinal microbiome is characteristic of Parkinson’s disease (PD). Prebiotic fibers change the microbiome and this study sought to understand the utility of prebiotic fibers for use in PD patients. The first experiments demonstrate that fermentation of PD patient stool with prebiotic fibers increased the production of beneficial metabolites (short chain fatty acids, SCFA) and changed the microbiota demonstrating the capacity of PD microbiota to respond favorably to prebiotics. Subsequently, an open-label, non-randomized study was conducted in newly diagnosed, non-medicated (n = 10) and treated PD participants (n = 10) wherein the impact of 10 days of prebiotic intervention was evaluated. Outcomes demonstrate that the prebiotic intervention was well tolerated (primary outcome) and safe (secondary outcome) in PD participants and was associated with beneficial biological changes in the microbiota, SCFA, inflammation, and neurofilament light chain. Exploratory analyses indicate effects on clinically relevant outcomes. This proof-of-concept study offers the scientific rationale for placebo-controlled trials using prebiotic fibers in PD patients. ClinicalTrials.gov Identifier: NCT04512599.
format Online
Article
Text
id pubmed-9938693
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-99386932023-02-20 An open label, non-randomized study assessing a prebiotic fiber intervention in a small cohort of Parkinson’s disease participants Hall, Deborah A. Voigt, Robin M. Cantu-Jungles, Thaisa M. Hamaker, Bruce Engen, Phillip A. Shaikh, Maliha Raeisi, Shohreh Green, Stefan J. Naqib, Ankur Forsyth, Christopher B. Chen, Tingting Manfready, Richard Ouyang, Bichun Rasmussen, Heather E. Sedghi, Shahriar Goetz, Christopher G. Keshavarzian, Ali Nat Commun Article A pro-inflammatory intestinal microbiome is characteristic of Parkinson’s disease (PD). Prebiotic fibers change the microbiome and this study sought to understand the utility of prebiotic fibers for use in PD patients. The first experiments demonstrate that fermentation of PD patient stool with prebiotic fibers increased the production of beneficial metabolites (short chain fatty acids, SCFA) and changed the microbiota demonstrating the capacity of PD microbiota to respond favorably to prebiotics. Subsequently, an open-label, non-randomized study was conducted in newly diagnosed, non-medicated (n = 10) and treated PD participants (n = 10) wherein the impact of 10 days of prebiotic intervention was evaluated. Outcomes demonstrate that the prebiotic intervention was well tolerated (primary outcome) and safe (secondary outcome) in PD participants and was associated with beneficial biological changes in the microbiota, SCFA, inflammation, and neurofilament light chain. Exploratory analyses indicate effects on clinically relevant outcomes. This proof-of-concept study offers the scientific rationale for placebo-controlled trials using prebiotic fibers in PD patients. ClinicalTrials.gov Identifier: NCT04512599. Nature Publishing Group UK 2023-02-18 /pmc/articles/PMC9938693/ /pubmed/36801916 http://dx.doi.org/10.1038/s41467-023-36497-x Text en © This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Hall, Deborah A.
Voigt, Robin M.
Cantu-Jungles, Thaisa M.
Hamaker, Bruce
Engen, Phillip A.
Shaikh, Maliha
Raeisi, Shohreh
Green, Stefan J.
Naqib, Ankur
Forsyth, Christopher B.
Chen, Tingting
Manfready, Richard
Ouyang, Bichun
Rasmussen, Heather E.
Sedghi, Shahriar
Goetz, Christopher G.
Keshavarzian, Ali
An open label, non-randomized study assessing a prebiotic fiber intervention in a small cohort of Parkinson’s disease participants
title An open label, non-randomized study assessing a prebiotic fiber intervention in a small cohort of Parkinson’s disease participants
title_full An open label, non-randomized study assessing a prebiotic fiber intervention in a small cohort of Parkinson’s disease participants
title_fullStr An open label, non-randomized study assessing a prebiotic fiber intervention in a small cohort of Parkinson’s disease participants
title_full_unstemmed An open label, non-randomized study assessing a prebiotic fiber intervention in a small cohort of Parkinson’s disease participants
title_short An open label, non-randomized study assessing a prebiotic fiber intervention in a small cohort of Parkinson’s disease participants
title_sort open label, non-randomized study assessing a prebiotic fiber intervention in a small cohort of parkinson’s disease participants
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9938693/
https://www.ncbi.nlm.nih.gov/pubmed/36801916
http://dx.doi.org/10.1038/s41467-023-36497-x
work_keys_str_mv AT halldeboraha anopenlabelnonrandomizedstudyassessingaprebioticfiberinterventioninasmallcohortofparkinsonsdiseaseparticipants
AT voigtrobinm anopenlabelnonrandomizedstudyassessingaprebioticfiberinterventioninasmallcohortofparkinsonsdiseaseparticipants
AT cantujunglesthaisam anopenlabelnonrandomizedstudyassessingaprebioticfiberinterventioninasmallcohortofparkinsonsdiseaseparticipants
AT hamakerbruce anopenlabelnonrandomizedstudyassessingaprebioticfiberinterventioninasmallcohortofparkinsonsdiseaseparticipants
AT engenphillipa anopenlabelnonrandomizedstudyassessingaprebioticfiberinterventioninasmallcohortofparkinsonsdiseaseparticipants
AT shaikhmaliha anopenlabelnonrandomizedstudyassessingaprebioticfiberinterventioninasmallcohortofparkinsonsdiseaseparticipants
AT raeisishohreh anopenlabelnonrandomizedstudyassessingaprebioticfiberinterventioninasmallcohortofparkinsonsdiseaseparticipants
AT greenstefanj anopenlabelnonrandomizedstudyassessingaprebioticfiberinterventioninasmallcohortofparkinsonsdiseaseparticipants
AT naqibankur anopenlabelnonrandomizedstudyassessingaprebioticfiberinterventioninasmallcohortofparkinsonsdiseaseparticipants
AT forsythchristopherb anopenlabelnonrandomizedstudyassessingaprebioticfiberinterventioninasmallcohortofparkinsonsdiseaseparticipants
AT chentingting anopenlabelnonrandomizedstudyassessingaprebioticfiberinterventioninasmallcohortofparkinsonsdiseaseparticipants
AT manfreadyrichard anopenlabelnonrandomizedstudyassessingaprebioticfiberinterventioninasmallcohortofparkinsonsdiseaseparticipants
AT ouyangbichun anopenlabelnonrandomizedstudyassessingaprebioticfiberinterventioninasmallcohortofparkinsonsdiseaseparticipants
AT rasmussenheathere anopenlabelnonrandomizedstudyassessingaprebioticfiberinterventioninasmallcohortofparkinsonsdiseaseparticipants
AT sedghishahriar anopenlabelnonrandomizedstudyassessingaprebioticfiberinterventioninasmallcohortofparkinsonsdiseaseparticipants
AT goetzchristopherg anopenlabelnonrandomizedstudyassessingaprebioticfiberinterventioninasmallcohortofparkinsonsdiseaseparticipants
AT keshavarzianali anopenlabelnonrandomizedstudyassessingaprebioticfiberinterventioninasmallcohortofparkinsonsdiseaseparticipants
AT halldeboraha openlabelnonrandomizedstudyassessingaprebioticfiberinterventioninasmallcohortofparkinsonsdiseaseparticipants
AT voigtrobinm openlabelnonrandomizedstudyassessingaprebioticfiberinterventioninasmallcohortofparkinsonsdiseaseparticipants
AT cantujunglesthaisam openlabelnonrandomizedstudyassessingaprebioticfiberinterventioninasmallcohortofparkinsonsdiseaseparticipants
AT hamakerbruce openlabelnonrandomizedstudyassessingaprebioticfiberinterventioninasmallcohortofparkinsonsdiseaseparticipants
AT engenphillipa openlabelnonrandomizedstudyassessingaprebioticfiberinterventioninasmallcohortofparkinsonsdiseaseparticipants
AT shaikhmaliha openlabelnonrandomizedstudyassessingaprebioticfiberinterventioninasmallcohortofparkinsonsdiseaseparticipants
AT raeisishohreh openlabelnonrandomizedstudyassessingaprebioticfiberinterventioninasmallcohortofparkinsonsdiseaseparticipants
AT greenstefanj openlabelnonrandomizedstudyassessingaprebioticfiberinterventioninasmallcohortofparkinsonsdiseaseparticipants
AT naqibankur openlabelnonrandomizedstudyassessingaprebioticfiberinterventioninasmallcohortofparkinsonsdiseaseparticipants
AT forsythchristopherb openlabelnonrandomizedstudyassessingaprebioticfiberinterventioninasmallcohortofparkinsonsdiseaseparticipants
AT chentingting openlabelnonrandomizedstudyassessingaprebioticfiberinterventioninasmallcohortofparkinsonsdiseaseparticipants
AT manfreadyrichard openlabelnonrandomizedstudyassessingaprebioticfiberinterventioninasmallcohortofparkinsonsdiseaseparticipants
AT ouyangbichun openlabelnonrandomizedstudyassessingaprebioticfiberinterventioninasmallcohortofparkinsonsdiseaseparticipants
AT rasmussenheathere openlabelnonrandomizedstudyassessingaprebioticfiberinterventioninasmallcohortofparkinsonsdiseaseparticipants
AT sedghishahriar openlabelnonrandomizedstudyassessingaprebioticfiberinterventioninasmallcohortofparkinsonsdiseaseparticipants
AT goetzchristopherg openlabelnonrandomizedstudyassessingaprebioticfiberinterventioninasmallcohortofparkinsonsdiseaseparticipants
AT keshavarzianali openlabelnonrandomizedstudyassessingaprebioticfiberinterventioninasmallcohortofparkinsonsdiseaseparticipants